These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6308771)

  • 21. Characterization of two antigens in parkinsonian Lewy bodies.
    Hirsch E; Ruberg M; Portier MM; Dardenne M; Agid Y
    Brain Res; 1988 Feb; 441(1-2):139-44. PubMed ID: 3359227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemistry of neuronal inclusions in the cerebral cortex and brain-stem in Lewy body disease.
    Fukuda T; Tanaka J; Watabe K; Numoto RT; Minamitani M
    Acta Pathol Jpn; 1993 Oct; 43(10):545-51. PubMed ID: 8291442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease.
    Lowe J; Blanchard A; Morrell K; Lennox G; Reynolds L; Billett M; Landon M; Mayer RJ
    J Pathol; 1988 May; 155(1):9-15. PubMed ID: 2837558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrastructure of Lewy bodies in the stellate ganglion.
    Forno LS; Norville RL
    Acta Neuropathol; 1976 Mar; 34(3):183-97. PubMed ID: 178142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies.
    Arima K; Uéda K; Sunohara N; Hirai S; Izumiyama Y; Tonozuka-Uehara H; Kawai M
    Brain Res; 1998 Oct; 808(1):93-100. PubMed ID: 9795161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Lewy bodies, a misleading marker for Parkinson's disease?].
    Duyckaerts C; Hauw JJ
    Bull Acad Natl Med; 2003; 187(2):277-92; discussion 292-3. PubMed ID: 14556441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pathological study of the association between Lewy body disease and Alzheimer's disease.
    Gibb WR; Mountjoy CQ; Mann DM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):701-8. PubMed ID: 2545826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system.
    Ohama E; Ikuta F
    Acta Neuropathol; 1976 Apr; 34(4):311-9. PubMed ID: 179263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
    Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
    J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dense core vesicles around the Lewy body in incidental Parkinson's disease: an electron microscopic study.
    Watanabe I; Vachal E; Tomita T
    Acta Neuropathol; 1977 Aug; 39(2):173-5. PubMed ID: 197775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease.
    Gertz HJ; Siegers A; Kuchinke J
    Brain Res; 1994 Feb; 637(1-2):339-41. PubMed ID: 8180816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease.
    Gai WP; Vickers JC; Blumbergs PC; Blessing WW
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1039-46. PubMed ID: 7916375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
    Spillantini MG; Goedert M
    Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microheterogeneity ("neurotypy") of neurofilament proteins.
    Goldstein ME; Sternberger LA; Sternberger NH
    Proc Natl Acad Sci U S A; 1983 May; 80(10):3101-5. PubMed ID: 6574474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation.
    Meredith GE; Halliday GM; Totterdell S
    Parkinsonism Relat Disord; 2004 Jun; 10(4):191-202. PubMed ID: 15120093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identities, antigenic determinants, and topographic distributions of neurofilament proteins in the nervous systems of adult frogs and tadpoles of Xenopus laevis.
    Szaro BG; Gainer H
    J Comp Neurol; 1988 Jul; 273(3):344-58. PubMed ID: 2463277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell death mechanisms in Parkinson's disease.
    Jellinger KA
    J Neural Transm (Vienna); 2000; 107(1):1-29. PubMed ID: 10809400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease.
    Lennox G; Lowe J; Morrell K; Landon M; Mayer RJ
    J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):67-71. PubMed ID: 2540286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pathology of the cytoskeleton in Alzheimer's disease and disorders related to this disease].
    Seitelberg F; Lassmann H
    Gac Med Mex; 1990; 126(5):367-73. PubMed ID: 1966495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.